Ophthalmic Therapeutic Innovation
Pre-clinicalOTI-2024, first in class and best in class adenosine drug, a new MMP agent removes the rate-limiting root causes of glaucoma
Founded
2018
Focus
Small Molecules
About
OTI-2024, first in class and best in class adenosine drug, a new MMP agent removes the rate-limiting root causes of glaucoma
Company Info
TypePrivate
Founded2018
LocationCambridge, United States
StagePre-clinical
Contact
Sectors
SIMILAR COMPANIES
BASi Research Products
Pre-clinical · West Lafayette
Bay BioSciences
Pre-clinical · San Francisco
EydisBio
Pre-clinical · Cambridge
3Spine
Pre-clinical · Memphis
Belcher Pharmaceuticals
Pre-clinical · Miami
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile